ALNYLAM PHARMACEUTICALS, INC. announced preliminary fourth quarter and full year 2022 global net product revenues of $262 million and $894 million respectively, and updated its cash guidance for the year ended December 31, 2022.
AI Assistant
ALNYLAM PHARMACEUTICALS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.